{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:45:06Z","timestamp":1789962306098,"version":"4.0.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>\n                    A retrospective analysis was conducted on the positive rate of HER2 in gastric cancer in the Chinese high-incidence area of Wuwei from 2015 to 2024. The pathological characteristics of HER2-positive gastric cancer were explored to provide a basis for precise diagnosis and treatment in high-incidence areas of gastric cancer. A retrospective study design was adopted to collect and analysis the HER2 expression status of gastric cancer surgical specimens from 2015 to 2024. A total of 416 gastric cancer surgical specimens were collected for HER2 detection, and the positive rate of HER2 was 9.13% (38\/416), including 33 males (9.68%) and 5 females (6.67%), with no statistical significance (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;.05). There were 24 (8.63%) HER2 positive patients over 60 years old, 11 (10.67%) HER2 positive patients between 50 and 59 years old, and 3 (8.6%) HER2 positive patients under 50 years old, with no statistical significance (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;.05). In cTNM stages, HER2 was positive in 7 patients (5.65%) in stage \u2160, 16 patients (10.32%) in stage \u2161, 14 patients (10.61%) in stage \u2162, and 1 patient (20%) in stage \u2163, with no statistical difference between groups (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;.05). The positive rate of tubular adenocarcinoma HER2 in WHO classification was 10.5%. Other tissue types were 0%, there were differences (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05); The positive rate of HER2 in well-differentiated adenocarcinoma was 10.84%, in moderately differentiated adenocarcinoma 16.44%, and in poorly differentiated adenocarcinoma 8.25%, with a difference between moderately and poorly differentiated adenocarcinoma (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). The positive rate of HER2 in T3 infiltration depth was 15.97% higher than that in T1\/T2\/T4 (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). The positive rate of HER2 in cardiac\/fundus was 16.26% higher than that in other sites (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). The proportion of patients with intestinal stype gastric cancer was the largest in Lauren classification (59.13%), but the HER2 positive rate of mixed type was significantly higher than that of other Lauren classification (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.001). Patients with lymph node metastasis (13%) were significantly higher than those without lymph node metastasis (4.66%), and the difference was statistically significant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.01). The research data indicate that correlation between the expression of HER2 in areas with a high incidence of gastric cancer and the pathological characteristics.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000047517","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:00:55Z","timestamp":1771005655000},"page":"e47517","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pathological characteristics and HER2 status of gastric cancer in Chinese high-incidence area"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0552-3900","authenticated-orcid":false,"given":"Huijuan","family":"Wang","sequence":"first","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxia","family":"Gao","sequence":"additional","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbing","family":"Li","sequence":"additional","affiliation":[{"name":"WuWei Center for Disease Control and Prevention, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichuan","family":"Chen","sequence":"additional","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuxue","family":"Ma","sequence":"additional","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqing","family":"Yan","sequence":"additional","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[{"name":"WuWei Hospital of Traditional Chinese Medicine, Wuwei, Gansu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9347-6567","authenticated-orcid":false,"given":"Xiaoyun","family":"Wu","sequence":"additional","affiliation":[{"name":"Liangzhou Hospital, Wuwei, Gansu Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260216","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20260216","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022.","volume":"4","author":"Han","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"R3-20260216","first-page":"221","article-title":"Analysis of malignant tumor prevalence in China in 2022.","volume":"46","author":"Zhang","year":"2024","journal-title":"Chin J Cancer"},{"key":"R4-20260216","first-page":"724","article-title":"Epidemiological characteristics and change trend of gastric cancer in Wuwei City, Gansu Province from 2010 to 2019.","volume":"33","author":"Gao","year":"2024","journal-title":"Chin Oncol"},{"key":"R5-20260216","first-page":"896","article-title":"Progress in comprehensive treatment of advanced gastric cancer.","volume":"51","author":"Gao","year":"2024","journal-title":"Chin Oncol Clin"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab incombination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial.","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/13543784.2011.566863","article-title":"New targeted therapies for gastric cancer.","volume":"20","author":"Asaoka","year":"2011","journal-title":"Expert Opin Investig Drugs"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12967-021-02842-1","article-title":"Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.","volume":"19","author":"Janusz Mezynski","year":"2021","journal-title":"J Transl Med"},{"key":"R9-20260216","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbcan.2019.03.003","article-title":"Targeting PI3K signaling in cancer: challenges and advances.","volume":"1871","author":"De Santis","year":"2019","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"188448","DOI":"10.1016\/j.bbcan.2020.188448","article-title":"New insights into affinity proteins for HER2-targeted therapy: beyond trastuzumab.","volume":"1874","author":"Akbari","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1515\/hsz-2016-0130","article-title":"The role of Her2 and other oncogenes of the PI3K\/AKT pathway in mitochondria.","volume":"397","author":"Rohlenova","year":"2016","journal-title":"Biol Chem"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"e53934","DOI":"10.7554\/eLife.53934","article-title":"Single-molecule functional anatomy of endogenous HER2-HER3 heterodimers.","volume":"9","author":"Choi","year":"2020","journal-title":"Elife"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives.","volume":"9","author":"Arteaga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","article-title":"HER2 expression status in diverse cancers: review of results from 37,992 patients.","volume":"34","author":"Yan","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"R15-20260216","first-page":"1047","article-title":"Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas.","volume":"77","author":"Sakai","year":"1986","journal-title":"J Natl Cancer Inst"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"e1567","DOI":"10.1002\/onco.13826","article-title":"Treatment patterns and outcomes in Chinese patients with gastric cancer by HER2 status: a noninterventional registry study (EVIDENCE).","volume":"26","author":"Qin","year":"2021","journal-title":"Oncologist"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1634\/theoncologist.2014-0378","article-title":"Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.","volume":"20","author":"Ali","year":"2015","journal-title":"Oncologist"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13073-017-0484-3","article-title":"Actionable gene-based classification toward precision medicine in gastric cancer.","volume":"9","author":"Ichikawa","year":"2017","journal-title":"Genome Med"},{"key":"R19-20260216","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1038\/onc.2010.112","article-title":"Oncogenic mutations regulate tumor micro- environment through induction of growth factors and angiogenic mediators.","volume":"29","author":"Wang","year":"2010","journal-title":"Oncogene"},{"key":"R20-20260216","doi-asserted-by":"crossref","first-page":"e27296","DOI":"10.4161\/onci.27296","article-title":"Anti-HER2\/Neu passive-aggressive immunotherapy.","volume":"3","author":"Mortenson","year":"2014","journal-title":"Oncoimmunology"},{"key":"R21-20260216","doi-asserted-by":"crossref","first-page":"8042","DOI":"10.18632\/oncotarget.24233","article-title":"MMTV-NeuT\/ATTAC mice: a new model for studying the stromal tumor microenvironment.","volume":"9","author":"Yuan","year":"2018","journal-title":"Oncotarget"},{"key":"R22-20260216","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12951-023-01810-9","article-title":"Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2\/Her2-specific CAR-macrophages for brainstem glioma immuno- therapy.","volume":"21","author":"Gao","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"R23-20260216","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/PAI.0000000000000423","article-title":"HER2 status in gastric and gastroesophageal junction cancer: results of the large, multinational HER-EAGLE study.","volume":"26","author":"Kim","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"R24-20260216","first-page":"1189","article-title":"Chinese expert consensus on anti-HER2 treatment of gastric cancer (2024).","volume":"51","author":"Liang","year":"2024","journal-title":"Chin Oncol Clin"},{"key":"R25-20260216","first-page":"822","article-title":"Analysis of multi-center detection results of HER2 in 40,842 Chinese patients with gastric adenocarcinoma.","volume":"47","author":"Huang","year":"2018","journal-title":"Chin J Pathol"},{"key":"R26-20260216","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10120-014-0453-0","article-title":"HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance.","volume":"19","author":"Huang","year":"2016","journal-title":"Gastric Cancer"},{"key":"R27-20260216","first-page":"2014","article-title":"Research progress of HER2 heterogeneity in gastric cancer.","volume":"39","author":"Wei","year":"2019","journal-title":"Chin J Clin Pathol"},{"key":"R28-20260216","doi-asserted-by":"crossref","first-page":"e0143207","DOI":"10.1371\/journal.pone.0143207","article-title":"Intra-tumoral heterogeneity of HER2, FGFR2, cMET and ATM in gastric cancer: optimizing personalized healthcare through innovative pathological and statistical analysis.","volume":"10","author":"Ye","year":"2015","journal-title":"PLoS One"},{"key":"R29-20260216","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s10120-014-0402-y","article-title":"HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.","volume":"18","author":"Van Cutsem","year":"2015","journal-title":"Gastric Cancer"},{"key":"R30-20260216","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","article-title":"Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRI O-013\/LOGiC--a randomized phase III trial.","volume":"34","author":"Hecht","year":"2015","journal-title":"J Clin Oncol"},{"key":"R31-20260216","first-page":"1","article-title":"Research progress on high-incidence of gastic cancer in China.","volume":"10","author":"Liu","year":"2024","journal-title":"Electronic J Comprehensive Cancer Ther"},{"key":"R33-20260216","first-page":"829","article-title":"Estimation study of new cancer cases and deaths in Wuwei, Hexi Corridor Region, China, 2018.","volume":"30","author":"Cao","year":"2017","journal-title":"Biomed Environ Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047517","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:24Z","timestamp":1771257744000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047517","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2025-09-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}